

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

TAKEDA PHARMACEUTICAL CO., LTD.,  
TAKEDA PHARMACEUTICALS NORTH  
AMERICA, INC., TAKEDA  
PHARMACEUTICALS LLC, AND TAKEDA  
PHARMACEUTICALS AMERICA, INC.,

Plaintiffs,

vs.

HANDA PHARMACEUTICALS, LLC., AND  
PAR PHARMACEUTICALS, INC.,

Defendants.

Case No. 3:11-cv-00840 JCS

[PROPOSED] FINAL JUDGMENT AS TO  
HANDA PHARMACEUTICALS, LLC.,  
AND PAR PHARMACEUTICALS, INC.

Judge: Hon. Joseph C. Spero  
Courtroom G, 15<sup>th</sup> Floor

Related Cases: 3:11-cv-01609 (JCS)  
3:11-cv-01610 (JCS)

1        This action having come before the Court for a bench trial from June 5 to June 12, 2013;  
 2 the issues having been heard and a decision having been rendered:

3           **IT IS HEREBY ORDERED AND ADJUDGED** this 1st day of November, 2013, for  
 4 the reasons set forth in the Court's Findings of Fact and Conclusions of Law [D.N. 446] dated  
 5 October 17, 2013, that Judgment shall be entered in favor of Plaintiffs Takeda Pharmaceuticals  
 6 Co., Ltd., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals LLC, and  
 7 Takeda Pharmaceuticals America, Inc. (collectively, "Takeda"), and against Defendants Handa  
 8 Pharmaceuticals, LLC, and Par Pharmaceuticals, Inc. (collectively, "Handa/Par"), on Takeda's  
 9 claims that Handa/Par's proposed products described in Abbreviated New Drug Application  
 10 ("ANDA") No. 202-294 infringe asserted claims 2 and 3 of U.S. Patent No. 6,664,276 ("the '276  
 11 Patent") and asserted claims 1 and 2 of U.S. Patent No. 7,737,282 ("the '282 Patent") pursuant to  
 12 35 U.S.C. § 271(e)(2); and it is further,

13           **ORDERED AND ADJUDGED** that the asserted claims of the '276 and '282 Patents are  
 14 valid and enforceable, and that Judgment shall be entered in favor of Takeda and against  
 15 Handa/Par on all counterclaims and defenses alleging noninfringement, invalidity, or  
 16 unenforceability of the '276 and '282 Patents; and it is further,

17           **ORDERED AND ADJUDGED**, pursuant to the Court's Order Re Summary Judgment  
 18 [D.N. 265] dated April 8, 2013, that Judgment shall be entered in favor of Handa/Par and against  
 19 Takeda on Takeda's claim that Handa/Par's proposed products described in ANDA No. 202-294  
 20 infringe asserted claims 2, 4, and 6 of U.S. Patent No. 7,790,755 ("the '755 Patent"); and it is  
 21 further,


22           **ORDERED AND ADJUDGED** that Judgment shall be entered in favor of Handa/Par and  
 23 against Takeda on Handa/Par's counterclaim alleging noninfringement of asserted claims 2, 4, and  
 24 6 of the '755 patent, and that Handa/Par's counterclaims and defenses alleging invalidity and  
 25 unenforceability of the '755 Patent are moot; and it is further,

26           **ORDERED** that, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval  
 27 by the United States Food and Drug Administration of Handa/Par's proposed products described  
 28 in ANDA No. 202-294 shall be a date that is not earlier than the last date of expiration of the '276

1 and '282 Patents (currently, June 15, 2020, for the '282 Patent, and December 15, 2020, with  
2 attached six months of pediatric exclusivity for the'276 Patent, which date is subject to extension  
3 pursuant to Takeda's request for patent term extension currently pending before the U.S. Patent  
4 and Trademark Office); and it is further,

5 ~~ORDERED~~ that, pursuant to Civil L.R. 54-1, costs shall be awarded to Takeda. JCS

6  
7 DATED: 11/1, 2013  
8



10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

1 Presented by,

2 DATED: October 25, 2013

MUNGER, TOLLES & OLSON LLP

3  
4 By: /s/ Heather E. Takahashi

5 JEFFREY I. WEINBERGER (SBN 056214)

6 *jeffrey.weinberger@mto.com*

7 TED G. DANE (SBN 143195)

8 *ted.dane@mto.com*

9 HEATHER E. TAKAHASHI (SBN 245845)

10 *heather.takahashi@mto.com*

11 RYAN N. HAGGLUND (*pro hac vice*)

12 *ryan.hagglund@mto.com*

13 MUNGER, TOLLES & OLSON LLP

14 355 South Grand Avenue, 35th Floor

15 Los Angeles, CA 90071-1560

16 Telephone: (213) 683-9100

17 Facsimile: (213) 687-3702

18 TINA W. ARROYO (State Bar No. 272757)

19 *tina.arroyo@mto.com*

20 MUNGER, TOLLES & OLSON LLP

21 560 Mission Street

22 San Francisco, California 94105-2907

23 Telephone: (415) 512-4000

24 Facsimile: (415) 512-4077

25 Attorneys for Plaintiffs

26 TAKEDA PHARMACEUTICAL CO., LTD.,

27 TAKEDA PHARMACEUTICALS NORTH

28 AMERICA, INC., TAKEDA PHARMACEUTICALS

21940134 LLC, AND TAKEDA PHARMACEUTICALS

21940134 AMERICA, INC.